Navigation Links
Marrone Bio Innovations Submits New Bioherbicide for EPA Registration
Date:2/25/2013

Davis, CA (PRWEB) February 25, 2013

Marrone Bio Innovations, Inc. (MBI), a leading global provider of natural pest management products for the agricultural and water treatment markets, announces the submission of a new bioherbicide, MBI-011 EP, to the U. S. Environmental Protection Agency (EPA). This is the second bioherbicide MBI has submitted for approval to the EPA (MBI-005 bioherbicide was EPA-approved in 2012). MBI-011 EP is a post-emergent burndown herbicide that can also be used as a crop desiccant. It has contact activity and no post-application planting restrictions are expected. MBI-011 EP is being submitted for control of annual and perennial grass and broadleaf weeds in the agricultural, non-crop and consumer home and garden markets.

Dr. Phyllis Himmel, MBI vice president of research and development, noted how the product got its start when one of MBI’s chemists screened for herbicidal activity of medicinal herbs. During the testing of 350 different herbs, an extract of dry long pepper (Piper longum L.) fruits showed activity against lettuce seedlings. This active ingredient was identified as sarmentine, a naturally occurring compound that gives black pepper its pungent aroma.

The new bioherbicide offers broad-spectrum control and will provide an alternative to herbicides that are highly prone to resistance. According to the International Survey of Herbicide Resistant Weeds, weeds have developed resistance to 148 different herbicides in 63 crops in 61 countries. “With the continuing and widespread identification of herbicide resistant weeds, we are very excited about submitting this product for registration,” remarks Dr. Pam Marrone, CEO. “It has become increasingly clear that no one product can be the ultimate solution to a weed problem and herbicide users need an array of tools to
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Marrone Bio Innovations’ Zequanox® Demonstrates Control of Zebra Mussels in Illinois Lake
2. Marrone Bio Innovations’ CEO to Address European Biopesticide Industry at Informa Life Sciences Biopesticides Conference
3. Marrone Bio Innovations Breaks Ground on Michigan Manufacturing Facility
4. Genomic Health Announces Results from Two Studies Demonstrating Innovations in Next Generation Sequencing From Paraffin Tissue, Enhancing Understanding of Tumor Biology
5. Brain Research Foundation 2013 Scientific Innovations Awards To Dr. Jean Hebert and Dr. Brian Litt
6. Prism Awards Honor Innovations in ‘Ubiquitous’ Photonics Technology
7. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
8. Wake Forest Innovations Partners with Veterinary Bioscience Institute to Develop Educational Programs for Life Science Professionals
9. The Scientist Proudly Announces the Top 10 Innovations of 2012
10. New Report: "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance" Now Available at Twease.org
11. Heartland Plant Innovations Wins Kansas Bioscience Authority Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... -- Neogen Corporation (Nasdaq: NEOG ) advised market ... from new rodenticide research are premature. In its regular ... 22, 2014, Neogen,s CEO commented about several new developments ... "It was my intent Tuesday at our conference call ... type of rodenticide, but certainly not to give any ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... and rejected the previously announced unsolicited proposal from Astellas ... of $16.00 per share. After careful consideration of ... the CV Therapeutics board concluded that the Astellas proposal ...
... February 20 Nyenrode Business,Universiteit has awarded a ... the field of microeconomics, competitive strategy and cluster,theory. ... of the modern,field of strategy and the world,s ... and competitive strategy. Professor Porter will receive,the Honorary ...
... Guidance of $0.90 to $1.10 for 2009 and $1.50 to $1.70 ... ) today announced its financial results for the three and twelve ... of $0.90 to $1.10 for 2009 and $1.50 to $1.70 for ... Adjusted diluted EPS of $0.26 ...
Cached Biology Technology:CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 2CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 3CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 4Nyenrode Honorary Doctorate for Professor Michael E. Porter 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 3Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 4Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 5Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 6Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 7Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 8Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 9Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 10Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 11Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 12Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 13Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 14Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 15Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 16Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 17
(Date:7/24/2014)... Parts of the primordial soup in which life arose have ... the University of East Anglia. , Research published today in ... in plants, yeast and very likely also in animals still ... origin of life some four billion years ago. , ... pond or ocean as a result of the combination of ...
(Date:7/24/2014)... Africa in mid-July 2014, as the annual fire season ... areas of increased temperatures, are heavily sprinkled across the ... Congo (northeast), and Zambia (southeast). Thick gray smoke rises ... especially in the Democratic Republic of the Congo, strong ... fire season is an annual event in this region, ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... group of European experts on biodiversity will gather from the ... to further improve the transfer of biodiversity knowledge from the ... will take part in a project funded by the European ... by researchers and practitioners to help all actors in the ...
... in milk powder and in meat-based baby food, residues ... the University of Almera (Spain) have developed a system ... such as tilmicosine, or antiparasitic drugs, such as levamisole, ... but they can remain later in food. Scientists from ...
... genetic testing that can indicate their range of risk ... appreciably drive up or diminish test recipients, demand for ... performed by researchers at the National Institutes of Health ... the May 17, 2012 early online issue of ...
Cached Biology News:A network of knowledge on biodiversity and ecosystem services in Europe 2A new method detects traces of veterinary drugs in baby food 2NIH-led study finds genetic test results do not trigger increased use of health services 2NIH-led study finds genetic test results do not trigger increased use of health services 3NIH-led study finds genetic test results do not trigger increased use of health services 4
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: